APYX · Apyx Medical Corporation Common Stock
View on chartInsiders & Stakes
| Stavros G. Vizirgianakis Director | ▲ Buy | Grant | 2,196,191 Shares held | 6/11/2026 | View profile |
| MAKRIDES ANDREW Director | ▼ Sell | Tax Withholding | 624,389 Shares held | 7/5/2022 | View profile |
| Moshe Citronowicz Sr. V.P. of Operations | ▲ Buy | Option Exercise | 493,504 Shares held | 3/15/2026 | View profile |
| Goodwin Charles D. II Chief Executive Officer | ▲ Buy | Open Market | 90,000 Shares held | 11/14/2023 | View profile |
| Geraghty Michael Director | ▲ Buy | Option Exercise | 27,500 Shares held | 6/6/2023 | View profile |
| Swandal Craig A. Director | ▲ Buy | Option Exercise | 17,000 Shares held | 3/21/2022 | View profile |
| Shawn David Roman Chief Operating Officer | ▼ Sell | Tax Withholding | 16,467 Shares held | 6/15/2026 | View profile |
| Lawrence Waldman Director | ▼ Sell | Tax Withholding | 12,314 Shares held | 6/30/2026 | View profile |
| Matthew C. Hill Chief Financial Officer | ▲ Buy | Open Market | 7,836 Shares held | 8/13/2024 | View profile |
| Hornsby Todd Executive Vice President | ▼ Sell | Open Market | 40 Shares held | 6/26/2023 | View profile |
Transaction History
| Lawrence Waldman | ▲ Buy | Option Exercise | 12,000 | $23K | 6/30/2026 |
| Lawrence Waldman | ▼ Sell | Tax Withholding | 5,024 | $23K | 6/30/2026 |
| Shawn David Roman | ▲ Buy | Option Exercise | 15,000 | $48K | 6/15/2026 |
| Shawn David Roman | ▼ Sell | Tax Withholding | 10,533 | $48K | 6/15/2026 |
| Stavros G. Vizirgianakis | ▲ Buy | Grant | 450,000 | $0 | 6/11/2026 |
| Moshe Citronowicz | ▲ Buy | Option Exercise | 37,000 | $67K | 3/15/2026 |
| Shawn David Roman | ▲ Buy | Option Exercise | 12,000 | $22K | 1/27/2026 |
| Matthew C. Hill | ▲ Buy | Open Market | 5,336 | $6K | 8/13/2024 |
| Matthew C. Hill | ▲ Buy | Open Market | 2,500 | $5K | 12/12/2023 |
| Goodwin Charles D. II | ▲ Buy | Open Market | 50,000 | $79K | 11/14/2023 |
| Lawrence Waldman | ▲ Buy | Option Exercise | 5,338 | $16K | 7/12/2023 |
| Hornsby Todd | ▲ Buy | Option Exercise | 15,000 | $27K | 6/26/2023 |
| Hornsby Todd | ▼ Sell | Open Market | 15,000 | $113K | 6/26/2023 |
| Geraghty Michael | ▲ Buy | Option Exercise | 10,000 | $28K | 6/6/2023 |
| Goodwin Charles D. II | ▲ Buy | Open Market | 2,000 | $12K | 8/29/2022 |
| Goodwin Charles D. II | ▲ Buy | Open Market | 9,750 | $58K | 8/29/2022 |
| Moshe Citronowicz | ▲ Buy | Option Exercise | 30,000 | $76K | 7/11/2022 |
| Lawrence Waldman | ▲ Buy | Option Exercise | 24,000 | $61K | 7/11/2022 |
| Geraghty Michael | ▲ Buy | Option Exercise | 4,000 | $10K | 7/6/2022 |
| MAKRIDES ANDREW | ▲ Buy | Option Exercise | 30,000 | $76K | 7/5/2022 |
| MAKRIDES ANDREW | ▼ Sell | Tax Withholding | 13,583 | $83K | 7/5/2022 |
| Lawrence Waldman | ▲ Buy | Option Exercise | 8,000 | $22K | 5/19/2022 |
| Geraghty Michael | ▲ Buy | Option Exercise | 6,000 | $17K | 5/11/2022 |
| Swandal Craig A. | ▲ Buy | Option Exercise | 17,000 | $85K | 3/21/2022 |
| Swandal Craig A. | ▲ Buy | Option Exercise | 7,173 | $68K | 1/7/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Apyx Medical featured in cold plasma market growth report
Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.
Apyx Medical featured in cold plasma market growth report. Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.